Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
about
Management of cytomegalovirus infection and disease in liver transplant recipients.Cytomegalovirus enhances macrophage TLR expression and MyD88-mediated signal transduction to potentiate inducible inflammatory responses.Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis.Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.Prevention of cytomegalovirus following solid organ transplantation: a literature review.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementUniversal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.Virus-specific T-cell therapy in solid organ transplantation.Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention.Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.Late cytomegalovirus infection in children: High incidence of allograft rejection and hepatitis in donor negative and seropositive liver transplant recipients.Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant.
P2860
Q33845124-EDAEE982-BCD2-4CCB-AF91-55CFC8E38CA3Q34550472-129964A1-2773-4E7F-A512-677FE9E07472Q38093577-3A513C39-04EA-40B2-9B0E-038F25C58153Q38099432-4937BABE-7724-4817-B4B9-7FF1E722D331Q38124439-05901752-CBE5-4BF7-AEC3-F15C1774E530Q38242802-AAFE5F64-77E5-40E2-8A4D-CCAFE2B4B8A5Q38293175-740EA527-E57D-430D-A612-7C6FED946579Q38568902-B6BF6279-CAEC-40EA-BB16-C5F229683534Q38689823-29407388-2E4C-41E0-BE66-5B963995EB5BQ39405795-58E0A5C6-6B22-4B81-A02A-463AB09ABE96Q40353704-3F52B9A6-AB2D-418B-9441-B47A097876DEQ41439136-DF8FA87B-DB3D-46AF-B29C-5EB2E7F14B0FQ41500588-FBBD5EBD-98E9-4330-B19D-F79C02129A1AQ42216221-6A55D7B1-2EE4-4351-9D73-8C0DC97211DDQ42234413-99F087E2-3CA4-4B26-BB43-2E37487DA5D5
P2860
Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Prophylaxis versus preemptive ...... k liver transplant recipients.
@en
Prophylaxis versus preemptive ...... k liver transplant recipients.
@nl
type
label
Prophylaxis versus preemptive ...... k liver transplant recipients.
@en
Prophylaxis versus preemptive ...... k liver transplant recipients.
@nl
prefLabel
Prophylaxis versus preemptive ...... k liver transplant recipients.
@en
Prophylaxis versus preemptive ...... k liver transplant recipients.
@nl
P2093
P2860
P50
P356
P1476
Prophylaxis versus preemptive ...... k liver transplant recipients.
@en
P2093
Antoni Rafecas
Carme Baliellas
Joan Fabregat
Jordi Carratalà
Jordi Niubó
Marta Bodro
P2860
P304
P356
10.1002/LT.23460
P577
2012-09-01T00:00:00Z